Go Pro
→ The hidden costs of a hands-off retirement account (From SmartAsset) (Ad)tc pixel Free COLL Stock Alerts

Collegium Pharmaceutical (COLL) Financials

Collegium Pharmaceutical logo
$22.77 +0.39 (+1.74%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$22.80 +0.03 (+0.13%)
As of 09/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Collegium Pharmaceutical

Annual Income Statements for Collegium Pharmaceutical

This table shows Collegium Pharmaceutical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -27 -94 -75 -39 -23 27 72 -25 48 69 63
Consolidated Net Income / (Loss)		 -27 -94 -75 -39 -23 27 72 -25 48 69 63
Net Income / (Loss) Continuing Operations		 -27 -94 -75 -39 -23 27 72 -25 48 69 63
Total Pre-Tax Income 		-27 -94 -75 -39 -23 28 -3.37 -29 76 99 93
Total Operating Income		 -27 -94 -75 -21 -24 56 18 33 167 170 180
Total Gross Profit		 0.00 1.50 26 115 103 180 151 209 326 377 463
Total Revenue		 0.00 1.71 28 280 297 310 277 464 567 631 781
Operating Revenue		 0.00 1.71 28 280 297 310 277 464 567 631 781
Total Cost of Revenue		 0.00 0.21 2.60 166 194 130 126 254 241 254 317
Operating Cost of Revenue		 0.00 0.21 2.60 166 194 130 126 254 241 254 317
Total Operating Expenses		 27 96 101 135 127 124 133 176 159 207 284
Selling, General & Admin Expense		 19 81 93 127 116 114 119 172 159 210 285
Other Special Charges / (Income)		 - - - - 0.00 0.00 - 0.00 0.00 -2.91 -1.18
Total Other Income / (Expense), net		 -0.35 -0.09 0.58 -18 1.03 -29 -21 -62 -91 -71 -87
Interest Expense		 -0.09 0.09 - 20 0.91 29 21 63 107 85 98
Interest & Investment Income		 -0.44 - 0.58 1.69 1.94 0.23 0.01 1.05 16 14 11
Income Tax Expense		 - - - 0.00 0.00 0.83 -75 -3.85 28 29 30
Basic Earnings per Share		 ($1.48) ($3.88) ($2.47) ($1.19) ($0.68) $0.78 $2.05 ($0.74) $1.43 $2.14 $1.98
Weighted Average Basic Shares Outstanding		 13.54M 24.26M 30.27M 32.95M 33.45M 34.41M 34.94M 33.83M 33.74M 32.27M 31.71M
Diluted Earnings per Share		 ($1.48) ($3.88) ($2.47) ($1.19) ($0.68) $0.76 $1.86 ($0.74) $1.29 $1.86 $1.73
Weighted Average Diluted Shares Outstanding		 13.54M 24.26M 30.27M 32.95M 33.45M 35.15M 41.05M 33.83M 41.79M 40.42M 39.70M
Weighted Average Basic & Diluted Shares Outstanding		 13.54M 24.26M 30.27M 32.95M 33.45M 34.76M 33.38M 34.07M 31.96M 31.49M 31.75M

Quarterly Income Statements for Collegium Pharmaceutical

This table shows Collegium Pharmaceutical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 32 28 20 9.34 13 2.42 12 32 17 14 -15
Consolidated Net Income / (Loss)		 32 28 20 9.34 13 2.42 12 32 17 14 -15
Net Income / (Loss) Continuing Operations		 32 28 20 9.34 13 2.42 12 32 17 14 -15
Total Pre-Tax Income 		47 37 29 16 17 3.12 17 43 29 19 -14
Total Operating Income		 62 49 47 35 38 22 35 62 61 31 3.70
Total Gross Profit		 95 91 91 97 98 97 108 129 128 117 110
Total Revenue		 150 145 145 159 182 178 188 209 205 194 200
Operating Revenue		 150 145 145 159 182 178 188 209 205 194 200
Total Cost of Revenue		 55 53 54 63 84 80 80 80 77 76 90
Operating Cost of Revenue		 55 53 54 63 84 80 80 80 77 76 90
Total Operating Expenses		 33 42 43 62 60 76 73 67 68 86 107
Selling, General & Admin Expense		 33 42 43 62 63 76 74 67 68 86 107
Other Special Charges / (Income)		 - 0.00 0.00 0.00 - -0.79 -0.36 -0.02 -0.02 0.00 0.00
Total Other Income / (Expense), net		 -15 -13 -18 -19 -21 -19 -18 -19 -32 -12 -17
Interest Expense		 19 17 23 23 23 21 20 22 35 16 20
Interest & Investment Income		 4.30 4.49 4.40 3.28 1.81 2.23 2.38 3.12 3.57 3.71 2.29
Income Tax Expense		 15 8.91 9.49 6.25 4.73 0.71 5.04 12 12 4.24 1.52
Basic Earnings per Share		 $0.95 $0.86 $0.60 $0.29 $0.39 $0.08 $0.38 $1.00 $0.52 $0.45 ($0.46)
Weighted Average Basic Shares Outstanding		 33.74M 32.33M 32.43M 32.26M 32.27M 31.79M 31.81M 31.57M 31.71M 32.09M 32.46M
Diluted Earnings per Share		 $0.93 $0.71 $0.52 $0.27 $0.36 $0.07 $0.34 $0.84 $0.48 $0.40 ($0.46)
Weighted Average Diluted Shares Outstanding		 41.79M 41.44M 40.38M 40.16M 40.42M 32.84M 39.08M 39.44M 39.70M 40.07M 32.46M
Weighted Average Basic & Diluted Shares Outstanding		 31.96M 32.72M 32.21M 32.25M 31.49M 32.14M 31.50M 31.61M 31.75M 32.43M 32.56M

Annual Cash Flow Statements for Collegium Pharmaceutical

This table details how cash moves in and out of Collegium Pharmaceutical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 94 58 -35 28 23 6.64 12 -13 64 -143 156
Net Cash From Operating Activities		 -22 -75 -67 169 28 94 104 124 275 205 329
Net Cash From Continuing Operating Activities		 -22 -75 -67 169 28 94 104 124 275 205 328
Net Income / (Loss) Continuing Operations		 -27 -94 -75 -39 -23 27 72 -25 48 69 63
Consolidated Net Income / (Loss)		 -27 -94 -75 -39 -23 27 72 -25 48 69 63
Depreciation Expense		 0.17 0.66 0.59 1.07 0.73 0.87 1.74 2.68 3.50 3.86 4.18
Amortization Expense		 -0.03 -0.03 -0.03 110 15 70 71 145 153 169 226
Non-Cash Adjustments To Reconcile Net Income		 2.22 5.79 26 140 30 21 65 0.35 47 48 61
Changes in Operating Assets and Liabilities, net		 3.34 13 -18 -42 5.42 -24 -105 1.66 23 -85 -26
Net Cash From Investing Activities		 -0.36 -2.98 -0.99 -24 -6.44 -374 -1.94 -574 -71 -288 -64
Net Cash From Continuing Investing Activities		 -0.36 -2.98 -0.99 -24 -6.44 -374 -1.94 -574 -71 -288 -64
Purchase of Property, Plant & Equipment		 -0.36 -0.48 -0.99 -5.48 -6.44 -5.55 -1.94 -1.62 -0.46 -1.65 -1.74
Acquisitions		 0.00 -2.50 - -19 0.00 -368 0.00 -572 0.00 -268 0.00
Purchase of Investments		 - - - - - - 0.00 0.00 -92 -111 -127
Sale and/or Maturity of Investments		 - - - - - - 0.00 0.00 22 93 65
Net Cash From Financing Activities		 116 136 33 -117 2.04 286 -89 437 -140 -61 -110
Net Cash From Continuing Financing Activities		 116 136 33 -117 2.04 286 -89 437 -140 -61 -110
Repayment of Debt		 -1.36 -2.67 -2.67 0.00 0.00 -49 -50 -75 -301 -272 -636
Repurchase of Common Equity		 - - - -0.03 0.00 0.00 -48 -14 -75 -60 -25
Issuance of Debt		 0.00 - - 10 0.00 330 0.00 518 235 0.00 565
Issuance of Common Equity		 72 138 35 1.12 0.82 0.76 0.76 0.34 0.46 0.83 1.36
Other Financing Activities, net		 0.52 0.44 0.67 -128 1.22 4.32 7.80 7.77 0.28 271 -16
Cash Interest Paid		 0.35 0.28 0.14 - 0.71 19 18 53 73 62 69
Cash Income Taxes Paid		 - - - 0.00 0.00 0.48 3.01 10 24 52 60

Quarterly Cash Flow Statements for Collegium Pharmaceutical

This table details how cash moves in and out of Collegium Pharmaceutical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -20 -10 -56 -109 32 20 21 33 81 37 -139
Net Cash From Operating Activities		 73 62 67 -9.00 85 55 72 78 123 57 71
Net Cash From Continuing Operating Activities		 73 62 67 -9.47 85 55 72 78 122 57 71
Net Income / (Loss) Continuing Operations		 32 28 20 9.34 13 2.42 12 32 17 14 -15
Consolidated Net Income / (Loss)		 32 28 20 9.34 13 2.42 12 32 17 14 -15
Depreciation Expense		 0.95 0.92 0.95 0.95 1.04 1.09 1.14 1.03 0.92 0.46 1.81
Amortization Expense		 36 36 35 41 57 57 57 57 56 56 64
Non-Cash Adjustments To Reconcile Net Income		 -11 -2.00 36 10 4.23 13 3.50 12 33 10 22
Changes in Operating Assets and Liabilities, net		 15 -0.58 -24 -71 11 -17 -0.75 -23 15 -24 -1.43
Net Cash From Investing Activities		 -25 -18 -8.91 -249 -12 -9.68 -2.92 -31 -20 1.63 -503
Net Cash From Continuing Investing Activities		 -25 -18 -8.91 -249 -12 -9.68 -2.92 -31 -20 1.63 -503
Purchase of Property, Plant & Equipment		 -0.16 -0.57 -0.27 -0.24 -0.57 -0.80 -0.07 -0.19 -0.69 -0.27 -0.50
Purchase of Investments		 -41 -39 -34 -11 -27 -26 -17 -45 -39 -18 -1.99
Sale and/or Maturity of Investments		 16 22 26 29 16 17 14 15 20 20 155
Net Cash From Financing Activities		 -68 -54 -114 149 -41 -25 -48 -15 -22 -21 292
Net Cash From Continuing Financing Activities		 -68 -54 -114 149 -41 -25 -48 -15 -22 -21 292
Repayment of Debt		 -46 -46 -79 -165 17 -16 -16 -16 -587 -7.25 -7.25
Other Financing Activities, net		 3.01 -8.67 -0.16 0.01 280 -9.60 -7.12 0.47 0.12 -15 -0.17
Cash Interest Paid		 16 17 12 18 15 22 14 22 12 22 12
Cash Income Taxes Paid		 6.91 0.17 36 16 0.62 2.46 30 15 12 0.04 37

Annual Balance Sheets for Collegium Pharmaceutical

This table presents Collegium Pharmaceutical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 98 162 136 291 306 644 692 1,174 1,143 1,664 1,657
Total Current Assets		 97 159 133 238 256 278 316 420 538 482 691
Cash & Equivalents		 96 153 119 147 170 174 186 174 239 71 231
Restricted Cash		 - - - - - - - - 0.00 25 20
Short-Term Investments		 - - - - - - - 0.00 72 92 155
Accounts Receivable		 0.00 2.13 9.97 78 73 83 106 183 180 229 211
Inventories, net		 0.00 1.32 1.81 7.82 9.64 16 17 47 32 36 41
Prepaid Expenses		 1.19 1.91 3.01 5.12 3.11 4.84 5.88 17 15 30 33
Plant, Property, & Equipment, net		 0.74 1.04 1.83 9.27 12 19 19 20 16 14 12
Total Noncurrent Assets		 0.10 2.40 0.26 44 39 347 357 735 590 1,167 953
Goodwill		 0.00 2.10 - 44 30 336 0.00 134 134 162 146
Intangible Assets		 - - - - - - 269 567 422 891 670
Noncurrent Deferred & Refundable Income Taxes		 - - - - - - 78 24 26 98 113
Other Noncurrent Operating Assets		 0.00 0.20 0.16 0.20 9.23 8.51 7.73 6.96 7.90 15 25
Total Liabilities & Shareholders' Equity		 98 162 136 291 306 644 692 1,174 1,143 1,664 1,657
Total Liabilities		 13 27 31 200 219 458 489 979 948 1,435 1,355
Total Current Liabilities		 8.43 26 31 189 202 239 280 434 458 510 440
Short-Term Debt		 2.67 - 1.48 1.64 3.83 47 48 163 183 94 29
Accounts Payable		 3.54 9.11 5.68 12 6.25 10 4.19 3.49 8.69 3.93 11
Accrued Expenses		 2.23 8.88 24 175 191 181 226 267 265 411 381
Current Deferred Revenue		 0.00 7.61 - - - - - - - 0.00 0.67
Other Current Liabilities		 - - - - 0.66 0.73 0.81 1.11 0.99 1.27 19
Total Noncurrent Liabilities		 4.21 1.51 0.00 11 17 218 210 546 490 925 915
Long-Term Debt		 4.15 1.48 - 9.86 7.67 210 202 538 484 788 780
Noncurrent Deferred Revenue		 - - - - - - - - 0.00 10 9.11
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - - - - - - - 0.00
Other Noncurrent Operating Liabilities		 0.07 0.03 - 0.68 9.44 8.77 7.95 7.11 6.12 127 126
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 85 135 104 92 87 186 203 195 195 229 302
Total Preferred & Common Equity		 85 135 104 92 87 186 203 195 195 229 302
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00
Total Common Equity		 85 135 104 92 87 186 203 195 195 229 302
Common Stock		 214 358 402 429 447 519 502 538 566 590 625
Retained Earnings		 -129 -223 -298 -337 -360 -333 -256 -281 -233 -164 -101
Treasury Stock		 -0.00 - - - - - -43 -62 -137 -198 -223
Accumulated Other Comprehensive Income / (Loss)		 - - - - - - - 0.00 0.01 0.06 0.32

Quarterly Balance Sheets for Collegium Pharmaceutical

This table presents Collegium Pharmaceutical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 1,214 1,214 1,178 1,114 1,053 1,635 1,631 1,593 1,607 1,652 2,136
Total Current Assets		 498 537 537 539 510 444 528 549 614 746 608
Cash & Equivalents		 269 284 259 229 173 39 96 117 150 269 129
Restricted Cash		 - - - - - 25 20 20 20 20 20
Short-Term Investments		 - 42 46 89 99 81 102 105 136 153 0.00
Accounts Receivable		 179 167 182 175 184 228 229 213 234 229 285
Inventories, net		 33 26 34 31 28 38 37 38 38 43 113
Prepaid Expenses		 17 18 17 15 27 32 44 56 36 33 60
Plant, Property, & Equipment, net		 19 18 17 15 15 15 14 13 12 12 11
Total Noncurrent Assets		 697 659 624 560 528 1,177 1,090 1,031 981 895 1,517
Goodwill		 134 134 134 134 134 146 151 148 146 146 190
Intangible Assets		 530 493 456 387 353 947 836 780 725 614 1,186
Noncurrent Deferred & Refundable Income Taxes		 24 25 26 31 34 73 92 92 102 114 121
Other Noncurrent Operating Assets		 6.75 6.53 6.98 6.77 6.45 11 12 10 7.82 21 20
Total Liabilities & Shareholders' Equity		 1,214 1,214 1,178 1,114 1,053 1,635 1,631 1,593 1,607 1,652 2,136
Total Liabilities		 1,035 1,013 999 892 837 1,401 1,397 1,360 1,333 1,340 1,824
Total Current Liabilities		 413 435 465 446 462 459 487 465 453 435 590
Short-Term Debt		 183 183 183 183 183 94 89 65 65 50 71
Accounts Payable		 2.99 2.42 3.65 6.02 2.41 3.14 18 11 7.65 6.83 9.24
Accrued Expenses		 225 248 277 256 275 361 378 370 361 376 478
Current Deferred Revenue		 - - - - - - - - 0.67 0.67 0.67
Other Current Liabilities		 1.04 0.97 0.96 1.01 1.04 1.27 1.30 19 19 1.45 31
Total Noncurrent Liabilities		 622 578 534 446 375 941 910 896 880 905 1,234
Long-Term Debt		 615 571 528 440 369 803 773 758 744 770 1,037
Noncurrent Deferred Revenue		 - - - - - 10 10 10 9.28 8.94 8.78
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - - - - - - - 41
Other Noncurrent Operating Liabilities		 6.87 6.63 6.38 5.86 5.59 129 127 127 127 125 148
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 180 201 179 222 217 234 234 232 275 312 312
Total Preferred & Common Equity		 180 201 179 222 217 234 234 232 275 312 312
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 180 201 179 222 217 234 234 232 275 312 312
Common Stock		 540 549 546 565 568 583 593 599 615 622 636
Retained Earnings		 -299 -286 -265 -205 -186 -177 -162 -150 -118 -87 -102
Treasury Stock		 -62 -62 -102 -137 -165 -172 -198 -218 -223 -223 -223
Accumulated Other Comprehensive Income / (Loss)		 - -0.04 -0.05 -0.12 -0.18 0.39 0.24 0.34 0.29 -0.22 0.00

Annual Metrics And Ratios for Collegium Pharmaceutical

This table displays calculated financial ratios and metrics derived from Collegium Pharmaceutical's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - - - - - - 31,610,976.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 31,610,976.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - 1.99
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 1,564.29% 884.73% 5.81% 4.49% -10.69% 67.56% 22.17% 11.41% 23.62%
EBITDA Growth		 -16,831.25% -249.13% 19.87% 220.48% -109.16% 1,633.62% -29.04% 100.71% 79.25% 6.00% 19.51%
EBIT Growth		 0.00% -249.66% 19.81% 72.58% -14.81% 336.79% -68.65% 89.01% 401.10% 1.76% 5.73%
NOPAT Growth		 0.00% -249.66% 19.81% 72.58% -14.81% 428.09% -77.38% 89.01% 355.18% 12.34% 2.25%
Net Income Growth		 0.00% -245.54% 20.51% 47.74% 41.93% 217.74% 167.33% -134.96% 292.60% 43.68% -9.13%
EPS Growth		 93.49% -162.16% 36.34% 51.82% 42.86% 211.76% 144.74% -139.78% 274.32% 44.19% -6.99%
Operating Cash Flow Growth		 -20.17% -248.00% 10.71% 352.75% -83.60% 238.13% 10.24% 19.96% 121.16% -25.39% 60.66%
Free Cash Flow Firm Growth		 -1,774.46% -232.82% -6.97% 128.02% -31.06% -2,692.71% 105.25% -3,009.78% 163.31% -191.79% 228.35%
Invested Capital Growth		 -312.34% -333.23% 21.85% -229.04% -63.24% 474.83% -0.94% 172.62% -23.28% 67.11% -21.73%
Revenue Q/Q Growth		 0.00% 319.36% 49.99% 28.76% 0.26% 0.67% -15.01% 28.27% 3.68% 5.37% 3.10%
EBITDA Q/Q Growth		 -346.59% -89.35% 39.88% 97.42% -148.44% 35.35% -36.07% 68.46% 14.63% -0.83% 5.81%
EBIT Q/Q Growth		 -351.30% -89.23% 39.88% 58.02% -128.92% 44.69% -73.59% 365.28% 42.67% -12.19% 14.43%
NOPAT Q/Q Growth		 -275.91% -89.23% 39.88% 58.02% -128.92% 40.34% -92.36% 365.28% 113.62% -10.94% 7.45%
Net Income Q/Q Growth		 -2,060.79% -16.53% 11.95% 40.37% -98.71% 52.06% -30.91% 41.63% 434.11% -21.90% 7.57%
EPS Q/Q Growth		 78.83% -108.60% 17.11% 39.90% -106.06% 55.10% -29.01% 32.11% 760.00% -23.46% 7.45%
Operating Cash Flow Q/Q Growth		 -6.79% -23.64% 12.97% 48.84% -48.94% 7.95% 15.15% 32.01% 2.62% 5.84% 13.20%
Free Cash Flow Firm Q/Q Growth		 0.00% -93.29% 37.59% 115.43% -90.04% 2.74% -91.72% 19.78% 9.69% 6.01% 0.21%
Invested Capital Q/Q Growth		 13.44% -41.28% -42.42% -174.03% -22.40% -1.95% 3.92% -8.23% -5.52% -6.39% -7.10%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 87.55% 90.89% 40.92% 34.73% 58.01% 54.40% 45.15% 57.55% 59.76% 59.35%
EBITDA Margin		 0.00% -5,462.36% -262.98% 32.18% -2.79% 40.89% 32.49% 38.92% 57.10% 54.33% 52.52%
Operating Margin		 0.00% -5,498.66% -264.95% -7.38% -8.00% 18.14% 6.37% 7.18% 29.46% 26.91% 23.01%
EBIT Margin		 0.00% -5,498.66% -264.95% -7.38% -8.00% 18.14% 6.37% 7.18% 29.46% 26.91% 23.01%
Profit (Net Income) Margin		 0.00% -5,504.15% -262.91% -13.95% -7.66% 8.63% 25.83% -5.39% 8.50% 10.96% 8.05%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 96.99% -2,119.65% 86.67% 63.59% 70.20% 67.88%
Interest Burden Percent		 101.29% 100.10% 99.23% 189.16% 95.68% 49.05% -19.14% -86.58% 45.36% 58.02% 51.56%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 3.01% 0.00% 0.00% 36.41% 29.80% 32.12%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 55.83% 4.65% 4.74% 16.70% 16.18% 14.83%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 127.00% 88.33% -11.76% 3.53% 6.64% 4.23%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% -36.27% 32.12% -17.31% 7.98% 16.44% 8.87%
Return on Equity (ROE)		 -74.84% -85.62% -62.65% -39.99% -25.39% 19.57% 36.77% -12.57% 24.68% 32.62% 23.70%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -106.21% 5.60% -87.91% 43.04% -34.07% 39.21%
Operating Return on Assets (OROA)		 0.00% -72.44% -50.71% -9.69% -7.95% 11.84% 2.64% 3.57% 14.41% 12.11% 10.82%
Return on Assets (ROA)		 0.00% -72.52% -50.32% -18.34% -7.61% 5.63% 10.71% -2.68% 4.16% 4.93% 3.79%
Return on Common Equity (ROCE)		 4.39% -85.62% -62.65% -39.99% -25.39% 19.57% 36.77% -12.57% 24.68% 32.62% 23.70%
Return on Equity Simple (ROE_SIMPLE)		 -32.04% -69.81% -71.93% -42.72% -25.99% 14.38% 35.24% -12.83% 24.64% 30.23% 0.00%
Net Operating Profit after Tax (NOPAT)		 -19 -66 -53 -14 -17 55 12 23 106 119 122
NOPAT Margin		 0.00% -3,849.06% -185.46% -5.16% -5.60% 17.59% 4.46% 5.03% 18.73% 18.89% 15.62%
Net Nonoperating Expense Percent (NNEP)		 -21.68% -23.52% -16.39% -19.53% -4.15% -71.17% -83.68% 16.50% 13.16% 9.53% 10.60%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - 2.60% 12.31% 10.74% 10.80%
Cost of Revenue to Revenue		 0.00% 12.45% 9.11% 59.08% 65.27% 41.99% 45.60% 54.85% 42.45% 40.24% 40.65%
SG&A Expenses to Revenue		 0.00% 4,712.57% 325.73% 45.20% 39.25% 36.72% 42.97% 37.11% 28.09% 33.31% 36.49%
R&D to Revenue		 0.00% 873.64% 30.10% 3.09% 3.49% 3.15% 3.41% 0.86% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 5,586.21% 355.84% 48.29% 42.73% 39.87% 48.03% 37.97% 28.09% 32.85% 36.34%
Earnings before Interest and Taxes (EBIT)		 -27 -94 -75 -21 -24 56 18 33 167 170 180
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -27 -93 -75 90 -8.27 127 90 181 324 343 410
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 6.69 3.30 5.78 6.23 7.89 3.72 3.18 4.00 5.14 4.04 4.85
Price to Tangible Book Value (P/TBV)		 6.69 3.35 5.78 12.06 11.91 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 260.35 21.11 2.04 2.33 2.23 2.33 1.68 1.77 1.46 1.88
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 25.89 9.03 0.00 20.84 13.35 23.28
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 3.86% 11.08% 0.00% 4.80% 7.49% 4.30%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 2.91 2.69 1.82 2.46 1.75 2.61
Enterprise Value to Revenue (EV/Rev)		 0.00 171.67 16.99 1.55 1.79 2.50 2.56 2.82 2.40 2.56 2.41
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 4.83 0.00 6.12 7.89 7.23 4.20 4.72 4.60
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 13.79 40.24 39.20 8.15 9.52 10.49
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 14.22 57.48 56.00 12.81 13.56 15.45
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 2.57 19.13 8.26 6.85 10.51 4.95 7.89 5.72
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 27.52 48.69 0.00 47.74 0.00 4.97 0.00 5.84
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.08 0.01 0.01 0.13 0.13 1.38 1.23 3.60 3.41 3.85 2.74
Long-Term Debt to Equity		 0.05 0.01 0.00 0.11 0.09 1.13 0.99 2.76 2.48 3.44 2.59
Financial Leverage		 -1.07 -1.09 -1.13 -1.29 -1.64 -0.29 0.36 1.47 2.26 2.48 2.10
Leverage Ratio		 1.41 1.18 1.25 2.18 3.34 3.47 3.43 4.69 5.94 6.62 6.26
Compound Leverage Factor		 1.43 1.18 1.24 4.13 3.19 1.70 -0.66 -4.06 2.69 3.84 3.23
Debt to Total Capital		 7.41% 1.08% 1.40% 11.16% 11.62% 58.02% 55.19% 78.25% 77.34% 79.39% 73.27%
Short-Term Debt to Total Capital		 2.90% 0.00% 1.40% 1.59% 3.87% 10.72% 10.68% 18.14% 21.25% 8.42% 4.13%
Long-Term Debt to Total Capital		 4.51% 1.08% 0.00% 9.56% 7.75% 47.30% 44.52% 60.11% 56.09% 70.96% 69.14%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 92.59% 98.92% 98.60% 88.84% 88.38% 41.98% 44.81% 21.75% 22.66% 20.61% 26.73%
Debt to EBITDA		 -0.25 -0.02 -0.02 0.13 -1.39 2.03 2.78 3.88 2.06 2.57 2.02
Net Debt to EBITDA		 3.32 1.62 1.57 -1.50 19.18 0.65 0.71 2.92 1.10 2.02 1.03
Long-Term Debt to EBITDA		 -0.15 -0.02 0.00 0.11 -0.93 1.65 2.24 2.98 1.50 2.30 1.90
Debt to NOPAT		 -0.36 -0.02 -0.03 -0.79 -0.69 4.71 20.26 30.05 6.28 7.39 6.78
Net Debt to NOPAT		 4.72 2.30 2.22 9.33 9.54 1.52 5.15 22.61 3.36 5.82 3.45
Long-Term Debt to NOPAT		 -0.22 -0.02 0.00 -0.68 -0.46 3.84 16.34 23.09 4.56 6.61 6.40
Altman Z-Score		 25.32 7.01 7.65 1.02 1.17 1.02 0.82 0.62 1.41 0.95 1.57
Noncontrolling Interest Sharing Ratio		 105.87% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 11.49 6.20 4.24 1.26 1.27 1.16 1.13 0.97 1.17 0.95 1.57
Quick Ratio		 11.35 6.07 4.09 1.19 1.20 1.08 1.05 0.82 1.07 0.77 1.36
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -16 -53 -57 16 11 -283 15 -432 274 -251 322
Operating Cash Flow to CapEx		 -5,957.73% -15,734.38% -6,769.49% 3,092.75% 431.55% 1,693.87% 5,327.01% 7,659.06% 59,598.48% 12,407.99% 18,926.61%
Free Cash Flow to Firm to Interest Expense		 0.00 -562.04 0.00 0.79 12.01 -9.80 0.71 -6.84 2.56 -2.94 3.28
Operating Cash Flow to Interest Expense		 0.00 -798.44 0.00 8.41 30.56 3.25 4.93 1.97 2.57 2.40 3.35
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -803.51 0.00 8.14 23.48 3.06 4.84 1.94 2.57 2.38 3.33
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.01 0.19 1.31 0.99 0.65 0.41 0.50 0.49 0.45 0.47
Accounts Receivable Turnover		 0.00 0.00 4.71 6.38 3.93 3.97 2.93 3.21 3.13 3.09 3.55
Inventory Turnover		 0.00 0.00 1.66 34.41 22.18 10.31 7.65 7.96 6.10 7.49 8.30
Fixed Asset Turnover		 0.00 1.93 19.89 50.52 28.09 20.10 14.39 23.78 31.93 41.66 59.26
Accounts Payable Turnover		 0.00 0.03 0.35 18.58 21.05 16.01 17.78 66.24 39.49 40.25 43.49
Days Sales Outstanding (DSO)		 0.00 0.00 77.53 57.22 92.82 91.99 124.69 113.67 116.77 117.94 102.84
Days Inventory Outstanding (DIO)		 0.00 0.00 220.05 10.61 16.45 35.41 47.71 45.83 59.80 48.76 43.98
Days Payable Outstanding (DPO)		 0.00 10,832.62 1,040.14 19.64 17.34 22.80 20.53 5.51 9.24 9.07 8.39
Cash Conversion Cycle (CCC)		 0.00 -10,832.62 -742.55 48.18 91.93 104.60 151.87 153.99 167.33 157.63 138.43
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -3.91 -17 -13 -44 -71 266 264 720 552 923 722
Invested Capital Turnover		 0.00 -0.16 -1.89 -9.88 -5.18 3.17 1.04 0.94 0.89 0.86 0.95
Increase / (Decrease) in Invested Capital		 -2.96 -13 3.70 -30 -28 338 -2.52 456 -168 370 -200
Enterprise Value (EV)		 480 294 484 436 531 776 709 1,306 1,360 1,618 1,884
Market Capitalization		 569 445 601 571 690 693 646 779 1,004 924 1,464
Book Value per Share		 $4.11 $4.72 $3.20 $2.75 $2.61 $5.38 $5.87 $5.80 $5.99 $7.10 $9.54
Tangible Book Value per Share		 $4.11 $4.64 $3.20 $1.42 $1.73 ($4.33) ($1.90) ($15.08) ($11.04) ($25.58) ($16.25)
Total Capital		 92 136 106 103 99 443 453 896 863 1,110 1,129
Total Debt		 6.81 1.48 1.48 12 12 257 250 701 667 881 827
Total Long-Term Debt		 4.15 1.48 0.00 9.86 7.67 210 202 538 484 788 780
Net Debt		 -89 -152 -117 -135 -159 83 64 527 357 694 420
Capital Expenditures (CapEx)		 0.36 0.48 0.99 5.48 6.44 5.55 1.94 1.62 0.46 1.65 1.74
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.58 -20 -15 -97 -112 -88 -102 -25 -48 -121 -109
Debt-free Net Working Capital (DFNWC)		 91 133 103 50 58 86 84 149 263 66 298
Net Working Capital (NWC)		 88 133 102 48 54 38 36 -14 80 -27 251
Net Nonoperating Expense (NNE)		 8.42 28 22 25 6.10 28 -59 48 58 50 59
Net Nonoperating Obligations (NNO)		 -89 -152 -117 -135 -159 80 61 525 357 694 420
Total Depreciation and Amortization (D&A)		 0.14 0.62 0.56 111 15 71 72 147 157 173 230
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -1,183.28% -53.46% -34.45% -37.83% -28.45% -36.88% -5.37% -8.39% -19.24% -13.91%
Debt-free Net Working Capital to Revenue		 0.00% 7,772.00% 363.38% 17.84% 19.48% 27.72% 30.46% 32.07% 46.41% 10.50% 38.17%
Net Working Capital to Revenue		 0.00% 7,772.00% 358.18% 17.26% 18.19% 12.40% 12.99% -2.96% 14.06% -4.32% 32.21%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.48) ($3.88) ($2.47) ($1.19) ($0.68) $0.00 $0.00 $0.00 $1.43 $2.14 $1.98
Adjusted Weighted Average Basic Shares Outstanding		 23.51M 29.45M 32.99M 33.31M 34.05M 0.00 0.00 0.00 33.74M 32.27M 31.71M
Adjusted Diluted Earnings per Share		 ($1.48) ($94,176,000.00) ($2.47) ($1.19) ($0.68) $0.00 $0.00 $0.00 $1.29 $1.86 $1.73
Adjusted Weighted Average Diluted Shares Outstanding		 23.51M 29.45M 32.99M 33.31M 34.05M 0.00 0.00 0.00 41.79M 40.42M 39.70M
Adjusted Basic & Diluted Earnings per Share		 ($1.48) ($94,176,000.00) ($2.47) ($1.19) ($0.68) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 13.54M 24.26M 30.27M 32.95M 33.45M 0.00 0.00 0.00 31.96M 31.49M 31.75M
Normalized Net Operating Profit after Tax (NOPAT)		 -19 -66 -53 -14 -17 55 16 23 106 117 121
Normalized NOPAT Margin		 0.00% -3,849.06% -185.46% -5.16% -5.60% 17.59% 5.61% 5.03% 18.73% 18.56% 15.52%
Pre Tax Income Margin		 0.00% -5,504.15% -262.91% -13.95% -7.66% 8.90% -1.22% -6.22% 13.36% 15.61% 11.87%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 -1,000.87 0.00 -1.03 -26.13 1.95 0.84 0.53 1.56 1.99 1.83
NOPAT to Interest Expense		 0.00 -700.61 0.00 -0.72 -18.29 1.89 0.59 0.37 0.99 1.40 1.24
EBIT Less CapEx to Interest Expense		 0.00 -1,005.95 0.00 -1.30 -33.21 1.75 0.75 0.50 1.56 1.97 1.81
NOPAT Less CapEx to Interest Expense		 0.00 -705.69 0.00 -0.99 -25.37 1.70 0.49 0.34 0.99 1.38 1.22
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% -0.08% 0.00% 0.00% 66.92% -56.25% 155.75% 86.75% 39.93%

Quarterly Metrics And Ratios for Collegium Pharmaceutical

This table displays calculated financial ratios and metrics derived from Collegium Pharmaceutical's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - 31,610,976.00 31,753,211.00 32,433,779.00
DEI Adjusted Shares Outstanding		 - - - - - - - - 31,610,976.00 31,753,211.00 32,433,779.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - 0.54 0.46 -0.46
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 15.53% 0.11% 7.18% 16.53% 21.51% 22.66% 29.41% 31.42% 12.92% 8.87% 6.32%
EBITDA Growth		 72.15% 32.33% 10.07% -7.69% -2.92% -8.09% 10.72% 54.90% 23.52% 10.31% -25.11%
EBIT Growth		 424.69% 100.89% 33.22% -22.60% -38.22% -56.16% -26.05% 78.21% 59.42% 42.46% -89.47%
NOPAT Growth		 412.54% 117.17% 22.82% -35.31% -34.41% -55.15% -22.75% 115.75% 28.30% 42.34% -89.52%
Net Income Growth		 543.67% 259.03% 50.73% -54.76% -60.75% -91.28% -38.88% 237.51% 35.31% 499.75% -225.60%
EPS Growth		 542.86% 239.22% 52.94% -49.06% -61.29% -90.14% -34.62% 211.11% 33.33% 471.43% -235.29%
Operating Cash Flow Growth		 10.57% 123.83% -32.41% -112.16% 15.42% -10.56% 7.48% 971.63% 45.37% 3.10% -1.54%
Free Cash Flow Firm Growth		 146.87% 30.40% -23.74% -263.89% -263.48% -254.69% -277.56% 166.60% 168.84% 163.01% -55.62%
Invested Capital Growth		 -23.28% -25.47% -21.03% 68.66% 67.11% 67.06% 63.70% -21.13% -21.73% -21.37% 56.15%
Revenue Q/Q Growth		 9.54% -3.22% 0.24% 9.65% 14.22% -2.30% 5.76% 11.36% -1.87% -5.81% 3.29%
EBITDA Q/Q Growth		 17.71% -12.45% -2.84% -7.80% 23.80% -17.12% 17.04% 28.99% -1.28% -25.98% -20.55%
EBIT Q/Q Growth		 37.04% -19.80% -4.05% -26.61% 9.39% -43.10% 61.87% 76.86% -2.14% -49.15% -88.03%
NOPAT Q/Q Growth		 30.72% -11.25% -14.56% -34.74% 32.53% -39.31% 47.16% 82.27% -21.19% -32.67% -89.17%
Net Income Q/Q Growth		 54.79% -13.23% -29.25% -52.39% 34.29% -80.72% 395.78% 162.93% -46.16% -14.54% -203.83%
EPS Q/Q Growth		 75.47% -23.66% -26.76% -48.08% 33.33% -80.56% 385.71% 147.06% -42.86% -16.67% -215.00%
Operating Cash Flow Q/Q Growth		 -0.92% -15.55% 8.82% -113.35% 1,040.59% -34.55% 30.76% 8.28% 56.87% -53.58% 24.88%
Free Cash Flow Firm Q/Q Growth		 -9.64% 3.11% -24.39% -331.48% 9.86% 1.96% 13.20% 186.83% -6.83% -10.26% -314.36%
Invested Capital Q/Q Growth		 -5.52% -4.50% -5.60% 98.39% -6.39% -4.71% -7.50% -4.42% -7.10% -4.27% 83.70%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 63.19% 63.11% 62.51% 60.76% 54.02% 54.75% 57.65% 61.70% 62.49% 60.59% 55.18%
EBITDA Margin		 65.81% 59.53% 57.70% 48.51% 52.58% 44.61% 49.36% 57.18% 57.52% 45.20% 34.77%
Operating Margin		 41.20% 34.14% 32.68% 21.87% 20.95% 12.20% 18.67% 29.66% 29.57% 15.97% 1.85%
EBIT Margin		 41.20% 34.14% 32.68% 21.87% 20.95% 12.20% 18.67% 29.66% 29.57% 15.97% 1.85%
Profit (Net Income) Margin		 21.33% 19.12% 13.50% 5.86% 6.89% 1.36% 6.37% 15.05% 8.26% 7.49% -7.53%
Tax Burden Percent		 68.38% 75.67% 67.38% 59.92% 72.59% 77.42% 70.38% 72.54% 58.42% 77.35% 111.23%
Interest Burden Percent		 75.72% 74.02% 61.29% 44.72% 45.31% 14.40% 48.50% 69.96% 47.79% 60.66% -365.93%
Effective Tax Rate		 31.62% 24.33% 32.62% 40.08% 27.41% 22.58% 29.62% 27.46% 41.58% 22.65% 0.00%
Return on Invested Capital (ROIC)		 25.11% 23.77% 22.56% 10.00% 13.02% 8.93% 14.19% 18.48% 16.40% 12.53% 1.01%
ROIC Less NNEP Spread (ROIC-NNEP)		 22.79% 21.43% 19.06% 8.01% 10.14% 5.90% 11.23% 16.32% 13.07% 10.69% -1.29%
Return on Net Nonoperating Assets (RNNOA)		 51.46% 44.27% 32.35% 22.42% 25.11% 12.26% 21.55% 40.19% 27.45% 20.00% -3.64%
Return on Equity (ROE)		 76.57% 68.04% 54.91% 32.43% 38.13% 21.19% 35.74% 58.66% 43.85% 32.53% -2.64%
Cash Return on Invested Capital (CROIC)		 43.04% 51.55% 49.10% -34.05% -34.07% -36.58% -34.76% 36.50% 39.21% 40.58% -34.51%
Operating Return on Assets (OROA)		 20.15% 16.62% 16.62% 9.32% 9.42% 5.90% 9.98% 13.85% 13.90% 7.74% 0.80%
Return on Assets (ROA)		 10.43% 9.31% 6.86% 2.50% 3.10% 0.66% 3.41% 7.03% 3.88% 3.63% -3.26%
Return on Common Equity (ROCE)		 76.57% 68.04% 54.91% 32.43% 38.13% 21.19% 35.74% 58.66% 43.85% 32.53% -2.64%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 41.99% 46.12% 37.82% 0.00% 18.72% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 42 37 32 21 28 17 25 45 35 24 2.59
NOPAT Margin		 28.17% 25.83% 22.02% 13.10% 15.21% 9.45% 13.14% 21.51% 17.28% 12.35% 1.30%
Net Nonoperating Expense Percent (NNEP)		 2.32% 2.34% 3.50% 2.00% 2.88% 3.03% 2.96% 2.16% 3.33% 1.84% 2.29%
Return On Investment Capital (ROIC_SIMPLE)		 4.89% - - - 2.49% 1.53% 2.34% 4.16% 3.15% 2.11% 0.18%
Cost of Revenue to Revenue		 36.81% 36.89% 37.49% 39.24% 45.98% 45.25% 42.35% 38.30% 37.51% 39.41% 44.82%
SG&A Expenses to Revenue		 22.00% 28.97% 29.83% 38.89% 34.68% 42.99% 39.17% 32.05% 32.92% 44.62% 53.33%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 22.00% 28.97% 29.83% 38.89% 33.07% 42.55% 38.98% 32.04% 32.91% 44.62% 53.33%
Earnings before Interest and Taxes (EBIT)		 62 49 47 35 38 22 35 62 61 31 3.70
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 99 86 84 77 96 79 93 120 118 87 70
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 5.14 5.70 4.86 5.31 4.04 4.01 4.09 4.01 4.85 3.36 3.76
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 1.77 2.23 1.83 2.08 1.46 1.41 1.34 1.46 1.88 1.32 1.45
Price to Earnings (P/E)		 20.84 13.57 10.55 14.05 13.35 21.41 26.20 18.86 23.28 14.01 24.50
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 4.80% 7.37% 9.48% 7.12% 7.49% 4.67% 3.82% 5.30% 4.30% 7.14% 4.08%
Enterprise Value to Invested Capital (EV/IC)		 2.46 2.99 2.69 2.03 1.75 1.80 1.88 2.06 2.61 2.07 1.68
Enterprise Value to Revenue (EV/Rev)		 2.40 2.77 2.31 3.33 2.56 2.39 2.17 2.12 2.41 1.79 2.64
Enterprise Value to EBITDA (EV/EBITDA)		 4.20 4.56 3.79 5.77 4.72 4.71 4.44 4.14 4.60 3.42 5.40
Enterprise Value to EBIT (EV/EBIT)		 8.15 8.19 6.55 10.32 9.52 11.15 11.80 10.22 10.49 7.57 13.54
Enterprise Value to NOPAT (EV/NOPAT)		 12.81 11.41 9.26 14.91 13.56 16.53 17.25 14.14 15.45 10.93 21.95
Enterprise Value to Operating Cash Flow (EV/OCF)		 4.95 5.08 4.82 10.31 7.89 7.98 7.53 5.52 5.72 4.32 6.46
Enterprise Value to Free Cash Flow (EV/FCFF)		 4.97 4.95 4.83 0.00 0.00 0.00 0.00 4.99 5.84 4.48 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 3.41 2.80 2.55 3.83 3.85 3.68 3.54 2.94 2.74 2.63 3.55
Long-Term Debt to Equity		 2.48 1.98 1.71 3.43 3.44 3.30 3.27 2.71 2.59 2.47 3.32
Financial Leverage		 2.26 2.07 1.70 2.80 2.48 2.08 1.92 2.46 2.10 1.87 2.83
Leverage Ratio		 5.94 5.79 5.43 6.81 6.62 6.01 5.90 6.37 6.26 6.00 6.85
Compound Leverage Factor		 4.50 4.29 3.33 3.04 3.00 0.87 2.86 4.46 2.99 3.64 -25.07
Debt to Total Capital		 77.34% 73.72% 71.85% 79.28% 79.39% 78.62% 77.99% 74.62% 73.27% 72.42% 78.02%
Short-Term Debt to Total Capital		 21.25% 21.69% 23.83% 8.27% 8.42% 8.13% 6.12% 5.97% 4.13% 4.43% 4.97%
Long-Term Debt to Total Capital		 56.09% 52.03% 48.02% 71.00% 70.96% 70.50% 71.87% 68.66% 69.14% 67.99% 73.05%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 22.66% 26.28% 28.15% 20.72% 20.61% 21.38% 22.01% 25.38% 26.73% 27.58% 21.98%
Debt to EBITDA		 2.06 1.81 1.57 2.59 2.57 2.57 2.39 2.09 2.02 1.96 2.80
Net Debt to EBITDA		 1.10 0.89 0.80 2.17 2.02 1.92 1.68 1.30 1.03 0.91 2.43
Long-Term Debt to EBITDA		 1.50 1.28 1.05 2.32 2.30 2.30 2.20 1.92 1.90 1.84 2.63
Debt to NOPAT		 6.28 4.52 3.84 6.69 7.39 8.99 9.27 7.12 6.78 6.27 11.40
Net Debt to NOPAT		 3.36 2.21 1.95 5.61 5.82 6.72 6.54 4.43 3.45 2.90 9.86
Long-Term Debt to NOPAT		 4.56 3.19 2.56 5.99 6.61 8.06 8.54 6.55 6.40 5.89 10.67
Altman Z-Score		 1.11 1.35 1.26 0.81 0.68 0.75 0.87 1.11 1.34 1.17 0.71
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.17 1.21 1.11 0.97 0.95 1.08 1.18 1.36 1.57 1.71 1.03
Quick Ratio		 1.07 1.10 0.99 0.76 0.77 0.88 0.94 1.15 1.36 1.50 0.70
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 210 217 164 -380 -343 -336 -292 253 236 212 -454
Operating Cash Flow to CapEx		 44,718.29% 10,904.40% 24,962.22% -3,688.11% 14,849.82% 6,942.11% 111,444.62% 41,722.34% 17,858.93% 21,152.96% 14,379.64%
Free Cash Flow to Firm to Interest Expense		 10.88 12.53 7.22 -16.87 -15.13 -16.17 -14.26 11.64 6.69 13.35 -23.26
Operating Cash Flow to Interest Expense		 3.80 3.57 2.96 -0.40 3.74 2.66 3.54 3.60 3.49 3.60 3.65
Operating Cash Flow Less CapEx to Interest Expense		 3.80 3.54 2.95 -0.41 3.71 2.63 3.54 3.59 3.47 3.58 3.63
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.49 0.49 0.51 0.43 0.45 0.48 0.53 0.47 0.47 0.49 0.43
Accounts Receivable Turnover		 3.13 3.20 3.28 2.92 3.09 3.29 3.56 3.27 3.55 3.48 3.25
Inventory Turnover		 6.10 7.07 8.14 6.25 7.49 8.21 9.28 8.51 8.30 7.83 4.27
Fixed Asset Turnover		 31.93 33.02 34.93 38.34 41.66 45.33 50.72 56.37 59.26 62.43 68.62
Accounts Payable Turnover		 39.49 50.31 90.83 66.39 40.25 23.55 46.04 60.04 43.49 25.38 32.10
Days Sales Outstanding (DSO)		 116.77 113.90 111.19 124.96 117.94 110.83 102.45 111.47 102.84 104.84 112.48
Days Inventory Outstanding (DIO)		 59.80 51.66 44.81 58.38 48.76 44.47 39.34 42.87 43.98 46.60 85.52
Days Payable Outstanding (DPO)		 9.24 7.25 4.02 5.50 9.07 15.50 7.93 6.08 8.39 14.38 11.37
Cash Conversion Cycle (CCC)		 167.33 158.30 151.99 177.84 157.63 139.80 133.86 148.26 138.43 137.06 186.63
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 552 526 497 985 923 879 813 777 722 691 1,270
Invested Capital Turnover		 0.89 0.92 1.02 0.76 0.86 0.95 1.08 0.86 0.95 1.01 0.78
Increase / (Decrease) in Invested Capital		 -168 -180 -132 401 370 353 316 -208 -200 -188 457
Enterprise Value (EV)		 1,360 1,571 1,335 1,996 1,618 1,584 1,531 1,605 1,884 1,429 2,132
Market Capitalization		 1,004 1,266 1,053 1,245 924 940 950 1,102 1,464 1,050 1,174
Book Value per Share		 $5.99 $6.87 $6.62 $7.27 $7.10 $7.45 $7.22 $8.72 $9.54 $9.84 $9.62
Tangible Book Value per Share		 ($11.04) ($9.25) ($8.25) ($26.65) ($25.58) ($23.89) ($21.66) ($18.92) ($16.25) ($14.09) ($32.82)
Total Capital		 863 845 769 1,130 1,110 1,097 1,055 1,083 1,129 1,133 1,419
Total Debt		 667 623 553 896 881 862 823 808 827 820 1,107
Total Long-Term Debt		 484 440 369 803 788 773 758 744 780 770 1,037
Net Debt		 357 305 281 751 694 645 581 502 420 379 958
Capital Expenditures (CapEx)		 0.16 0.57 0.27 0.24 0.57 0.80 0.07 0.19 0.69 0.27 0.50
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -48 -42 -40 -67 -121 -88 -93 -80 -109 -81 -61
Debt-free Net Working Capital (DFNWC)		 263 276 232 78 66 130 149 226 298 361 89
Net Working Capital (NWC)		 80 93 48 -16 -27 41 85 161 251 311 18
Net Nonoperating Expense (NNE)		 10 9.73 12 12 15 14 13 14 19 9.40 18
Net Nonoperating Obligations (NNO)		 357 304 280 751 694 645 581 502 420 379 958
Total Depreciation and Amortization (D&A)		 37 37 36 42 58 58 58 58 57 57 66
Debt-free, Cash-free Net Working Capital to Revenue		 -8.39% -7.39% -6.90% -11.19% -19.24% -13.19% -13.12% -10.59% -13.91% -10.14% -7.50%
Debt-free Net Working Capital to Revenue		 46.41% 48.71% 40.20% 13.00% 10.50% 19.57% 21.11% 29.79% 38.17% 45.32% 10.98%
Net Working Capital to Revenue		 14.06% 16.37% 8.41% -2.61% -4.32% 6.15% 11.97% 21.26% 32.21% 39.02% 2.25%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.95 $0.86 $0.60 $0.29 $0.39 $0.08 $0.38 $1.00 $0.52 $0.45 ($0.46)
Adjusted Weighted Average Basic Shares Outstanding		 33.74M 32.33M 32.43M 32.26M 32.27M 31.79M 31.81M 31.57M 31.71M 32.09M 32.46M
Adjusted Diluted Earnings per Share		 $0.93 $0.71 $0.52 $0.27 $0.36 $0.07 $0.34 $0.84 $0.48 $0.40 ($0.46)
Adjusted Weighted Average Diluted Shares Outstanding		 41.79M 41.44M 40.38M 40.16M 40.42M 32.84M 39.08M 39.44M 39.70M 40.07M 32.46M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 31.96M 32.72M 32.21M 32.25M 31.49M 32.14M 31.50M 31.61M 31.75M 32.43M 32.56M
Normalized Net Operating Profit after Tax (NOPAT)		 42 37 32 21 28 16 24 45 35 24 2.59
Normalized NOPAT Margin		 28.17% 25.83% 22.02% 13.10% 15.21% 9.10% 13.01% 21.50% 17.27% 12.35% 1.30%
Pre Tax Income Margin		 31.19% 25.27% 20.03% 9.78% 9.49% 1.76% 9.06% 20.75% 14.13% 9.68% -6.77%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 3.20 2.85 2.08 1.55 1.68 1.04 1.72 2.85 1.72 1.95 0.19
NOPAT to Interest Expense		 2.19 2.16 1.40 0.93 1.22 0.81 1.21 2.07 1.01 1.51 0.13
EBIT Less CapEx to Interest Expense		 3.19 2.82 2.07 1.53 1.66 1.00 1.71 2.84 1.70 1.93 0.16
NOPAT Less CapEx to Interest Expense		 2.18 2.13 1.39 0.92 1.20 0.77 1.20 2.06 0.99 1.49 0.11
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 155.75% 80.39% 110.12% 67.72% 86.75% 0.00% 138.21% 85.77% 39.93% 0.00% 52.39%

Financials Breakdown Chart

Key Financial Trends

Collegium Pharmaceutical’s recent results show strong operating cash generation and multi-year revenue growth, but the second quarter of 2026 marked a sharp deterioration in profitability and liquidity. Revenue increased to $199.9 million in Q2 2026 from $188.0 million in the year-earlier quarter, continuing a broader growth trend from $123.5 million in Q2 2022. However, Q2 revenue was below the $205.4 million reported in Q4 2025.

  • Revenue has generally trended higher. Quarterly revenue rose from $123.5 million in Q2 2022 to $199.9 million in Q2 2026, with particularly strong growth through 2024 and 2025. Q2 2026 revenue was up approximately 6% year over year.
  • Operating cash flow remains consistently positive. Collegium generated $71.3 million of operating cash flow in Q2 2026, following $57.1 million in Q1 2026 and $122.1 million in Q4 2025. Except for Q3 2024, operating cash flow was positive in each reported quarter in the dataset.
  • Cash conversion benefits substantially from noncash amortization. Amortization expense was $64.0 million in Q2 2026, helping offset the reported net loss and support operating cash flow. This reflects the significant intangible-asset base on the balance sheet.
  • Accounts receivable has expanded alongside revenue. Accounts receivable increased from $167.5 million in Q2 2023 to $285.1 million in Q2 2026, consistent with the company’s larger revenue base, although investors should monitor collection trends.
  • Equity has improved from earlier periods. Total common equity increased to $311.9 million in Q2 2026 from $200.8 million in Q2 2023, supported by improved retained earnings and common-stock balances, despite the latest quarterly loss.
  • Q2 2026 included a significant investing cash outflow. Investing activities used $502.6 million, far more than the $2.9 million used in Q2 2025. The provided data shows investment sales of $155.3 million and only modest purchases of investments and property, so the full source of the outflow is not identifiable from the standardized line items supplied.
  • The balance sheet expanded substantially in Q2 2026. Total assets rose to $2.14 billion from $1.65 billion in Q1 2026, while intangible assets increased from $614.0 million to $1.19 billion and goodwill rose from $145.9 million to $190.2 million. This suggests a major acquisition or other asset transaction, although the supplied statements do not specify the cause.
  • Profitability deteriorated sharply in the latest quarter. Operating income fell to $3.7 million in Q2 2026 from $30.9 million in Q1 and $35.1 million in Q2 2025. The operating margin declined to approximately 1.9%, compared with 16.0% a year earlier.
  • Higher selling, general and administrative costs pressured earnings. SG&A increased to $106.6 million in Q2 2026 from $86.4 million in Q1 and $73.6 million in Q2 2025. SG&A consumed roughly 53% of revenue in the latest quarter, compared with about 39% a year earlier.
  • Collegium returned to a net loss. The company reported a Q2 2026 net loss of $15.1 million, or $0.46 per diluted share, compared with net income of $14.5 million in Q1 2026 and $12.0 million in Q2 2025.
  • Liquidity weakened materially during Q2. Cash and equivalents fell from $268.6 million at March 31, 2026, to $129.5 million at June 30, while short-term investments declined from $153.1 million to zero. Total current assets fell to $608.0 million from $745.7 million, bringing the current ratio close to 1.0.
  • Debt and interest costs remain significant. Total short- and long-term debt rose to approximately $1.11 billion in Q2 2026 from $820.3 million in Q1 and $822.9 million in Q2 2025. Interest expense increased to $19.5 million in Q2 2026, absorbing most of the company’s operating income.

Investor takeaway: Collegium’s long-term revenue trajectory and recurring operating cash flow are constructive, but the latest quarter introduces meaningful execution and balance-sheet risks. Investors should focus on whether the Q2 surge in intangible assets and debt translates into sustainable revenue and earnings growth, and whether management can restore operating margins while rebuilding unrestricted cash and reducing leverage.

09/20/26 02:36 AM ETAI Generated. May Contain Errors.

Collegium Pharmaceutical Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Collegium Pharmaceutical's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Collegium Pharmaceutical's net income appears to be on a downward trend, with a most recent value of $62.87 million in 2025, falling from -$27.26 million in 2015. The previous period was $69.19 million in 2024. See where experts think Collegium Pharmaceutical is headed by visiting Collegium Pharmaceutical's forecast page.

Collegium Pharmaceutical's total operating income in 2025 was $179.64 million, based on the following breakdown:
  • Total Gross Profit: $463.26 million
  • Total Operating Expenses: $283.62 million

Over the last 10 years, Collegium Pharmaceutical's total revenue changed from $0.00 in 2015 to $780.57 million in 2025, a change of 78,056,700,000.0%.

Collegium Pharmaceutical's total liabilities were at $1.36 billion at the end of 2025, a 5.5% decrease from 2024, and a 10,616.1% increase since 2015.

In the past 10 years, Collegium Pharmaceutical's cash and equivalents has ranged from $70.57 million in 2024 to $238.95 million in 2023, and is currently $231.25 million as of their latest financial filing in 2025.

Over the last 10 years, Collegium Pharmaceutical's book value per share changed from 4.11 in 2015 to 9.54 in 2025, a change of 132.1%.


Related Companies

Financial statements for NASDAQ:COLL last updated on 8/6/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
“Elon’s nightmare” could fund your retirement
Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...
Chaikin Analytics | Sponsoredtc pixel
You’ve never seen anything like this before
For centuries, families like the Rothschilds, Morgans, and Rockefellers have quietly used one overlooked type ...
Porter & Company | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
A “bloodbath” Is Coming
Reports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...
TradeSmith | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
The hidden costs of a hands-off retirement account
Contributing to your 401(k) consistently is good financial behavior - but contributing and optimizing are two ...
SmartAsset | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel